Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Merck & Co
(NY:
MRK
)
82.39
+0.58 (+0.71%)
Official Closing Price
Updated: 6:30 PM EDT, Jul 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
May 31, 2025
From
Merck & Co., Inc.
Via
Business Wire
Merck KANDLELIT Trials Spark Hope For Hard-To-Treat Cancers
May 30, 2025
Merck shared safety and efficacy results of MK-1084; either as monotherapy or in combinations, it demonstrated a manageable safety profile.
Via
Benzinga
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
May 30, 2025
There's a long history of anti-PD-1 and anti-VEGF drugs working to slow progression, but not improve overall survival.
Via
Investor's Business Daily
How Do Investors Really Feel About Merck & Co?
May 30, 2025
Via
Benzinga
Asia Summit on Global Health and Hong Kong International Medical and Healthcare Fair Wrap Up Successfully
May 28, 2025
From
HKTDC
Via
ACN Newswire
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
May 30, 2025
From
Merck & Co., Inc.
Via
Business Wire
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
May 30, 2025
From
Merck & Co., Inc.
Via
Business Wire
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
May 30, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
Merck, Daiichi Sankyo Pull FDA Application For Lung Cancer Therapy: Retail Terms It A ‘Huge Flop’
May 29, 2025
The decision is based on results from a late-stage trial in which the drug failed to prolong patients' lives, the companies stated.
Via
Stocktwits
Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45%
May 29, 2025
Keros ends PAH development of cibotercept after Phase 2 safety issues, including pericardial effusions, and plans to cut 45% of workforce amid review.
Via
Benzinga
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
May 29, 2025
From
Daiichi Sankyo
Via
Business Wire
10 Health Care Stocks Whale Activity In Today's Session
May 27, 2025
Via
Benzinga
Merck Announces Third-Quarter 2025 Dividend
May 27, 2025
From
Merck & Co., Inc.
Via
Business Wire
MERCK & CO. INC. (NYSE:MRK) - A Reliable Dividend Stock with Strong Fundamentals
May 27, 2025
MERCK & CO. (NYSE:MRK) offers a strong 4.2% dividend yield, consistent growth, and solid financial health, making it a top pick for dividend investors.
Via
Chartmill
"If Walmart Is Under Pressure to Raise Prices, It's Going to Have Broader Effects on the Economy."
May 27, 2025
Via
The Motley Fool
Topics
Earnings
Economy
World Trade
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
May 23, 2025
The companies are duking it out for the best treatment for head-and-neck cancer. One clearly has the edge.
Via
Investor's Business Daily
3 Dow Jones Stocks on Our Watchlist
May 23, 2025
The Dow Jones (^DJI) includes some of the most reliable stocks in the market, and while not all are equal, a few continue to shine. These companies are leveraging their strengths to maintain leadership...
Via
StockStory
Topics
Stocks
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
May 22, 2025
Via
Benzinga
Moderna Stock Looks Ripe for a Short Squeeze
May 22, 2025
Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze
Via
MarketBeat
Topics
Government
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
May 22, 2025
From
Merck & Co., Inc.
Via
Business Wire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
May 21, 2025
Via
The Motley Fool
Topics
Economy
Law Enforcement
Spotlight on Merck & Co: Analyzing the Surge in Options Activity
May 20, 2025
Via
Benzinga
MERCK & CO. INC. (NYSE:MRK) - A Strong Value Candidate in Pharmaceuticals
May 20, 2025
MERCK & CO. (NYSE:MRK) offers strong value with a low P/E ratio, high profitability, and a reliable dividend. A solid pick for value investors in the pharmaceutical sector.
Via
Chartmill
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
May 19, 2025
From
Daiichi Sankyo
Via
Business Wire
Got $100? 3 Top Growth Stocks to Buy That Could Double Your Money
May 18, 2025
Via
The Motley Fool
Topics
Artificial Intelligence
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
May 16, 2025
From
Merck & Co., Inc.
Via
Business Wire
Decoding Merck & Co's Options Activity: What's the Big Picture?
May 15, 2025
Via
Benzinga
Merck Data Shows Positive Outcomes For Ovarian Cancer Patients Treated With Keytruda
May 15, 2025
Merck's Phase 3 trial of Keytruda plus chemo met progression-free survival and overall survival goals in platinum-resistant ovarian cancer, including patients with PD-L1–positive tumors.
Via
Benzinga
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo
May 15, 2025
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels.
Via
Benzinga
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025
May 15, 2025
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.